FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308461004> ?p ?o ?g. }

• W4308461004 endingPage "353" @default.
• W4308461004 startingPage "333" @default.
• W4308461004 abstract "The U.S. Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative conducts active surveillance of adverse events of special interest (AESI) after COVID-19 vaccination. Historical incidence rates (IRs) of AESI are comparators to evaluate safety.We estimated IRs of 17 AESI in six administrative claims databases from January 1, 2019, to December 11, 2020: Medicare claims for adults ≥ 65 years and commercial claims (Blue Health Intelligence®, CVS Health, HealthCore Integrated Research Database, IBM® MarketScan® Commercial Database, Optum pre-adjudicated claims) for adults < 65 years. IRs were estimated by sex, age, race/ethnicity (Medicare), and nursing home residency (Medicare) in 2019 and for specific periods in 2020.The study included >100 million enrollees annually. In 2019, rates of most AESI increased with age. However, compared with commercially insured adults, Medicare enrollees had lower IRs of anaphylaxis (11 vs 12-19 per 100,000 person-years), appendicitis (80 vs 117-155), and narcolepsy (38 vs 41-53). Rates were higher in males than females for most AESI across databases and varied by race/ethnicity and nursing home status (Medicare). Acute myocardial infarction (Medicare) and anaphylaxis (all databases) IRs varied by season. IRs of most AESI were lower during March-May 2020 compared with March-May 2019 but returned to pre-pandemic levels after May 2020. However, rates of Bell's palsy, Guillain-Barré syndrome, narcolepsy, and hemorrhagic/non-hemorrhagic stroke remained lower in multiple databases after May 2020, whereas some AESI (e.g., disseminated intravascular coagulation) exhibited higher rates after May 2020 compared with 2019.AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety." @default.
• W4308461004 created "2022-11-12" @default.
• W4308461004 creator A5002078534 @default.
• W4308461004 creator A5007224336 @default.
• W4308461004 creator A5014773041 @default.
• W4308461004 creator A5018830827 @default.
• W4308461004 creator A5019939863 @default.
• W4308461004 creator A5021310689 @default.
• W4308461004 creator A5021773157 @default.
• W4308461004 creator A5022645240 @default.
• W4308461004 creator A5030066738 @default.
• W4308461004 creator A5034272918 @default.
• W4308461004 creator A5045519730 @default.
• W4308461004 creator A5046728330 @default.
• W4308461004 creator A5047323010 @default.
• W4308461004 creator A5048412798 @default.
• W4308461004 creator A5049812814 @default.
• W4308461004 creator A5050167270 @default.
• W4308461004 creator A5053965140 @default.
• W4308461004 creator A5057514738 @default.
• W4308461004 creator A5058653281 @default.
• W4308461004 creator A5063845988 @default.
• W4308461004 creator A5068452972 @default.
• W4308461004 creator A5069182342 @default.
• W4308461004 creator A5071144232 @default.
• W4308461004 creator A5071722590 @default.
• W4308461004 creator A5072427629 @default.
• W4308461004 creator A5074231210 @default.
• W4308461004 creator A5078200427 @default.
• W4308461004 creator A5078714872 @default.
• W4308461004 creator A5079140835 @default.
• W4308461004 creator A5082227471 @default.
• W4308461004 creator A5082658372 @default.
• W4308461004 creator A5087300873 @default.
• W4308461004 creator A5087332112 @default.
• W4308461004 creator A5087944869 @default.
• W4308461004 creator A5088786638 @default.
• W4308461004 creator A5091224699 @default.
• W4308461004 date "2023-01-01" @default.
• W4308461004 modified "2023-10-02" @default.
• W4308461004 title "Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020" @default.
• W4308461004 cites W3036829263 @default.
• W4308461004 cites W3081553985 @default.
• W4308461004 cites W3095526646 @default.
• W4308461004 cites W3096640075 @default.
• W4308461004 cites W3096854549 @default.
• W4308461004 cites W3097903491 @default.
• W4308461004 cites W3109622773 @default.
• W4308461004 cites W3134987890 @default.
• W4308461004 cites W3160661236 @default.
• W4308461004 cites W3161400598 @default.
• W4308461004 cites W3166109011 @default.
• W4308461004 cites W3174509543 @default.
• W4308461004 cites W3174930042 @default.
• W4308461004 cites W3177875708 @default.
• W4308461004 cites W3185635616 @default.
• W4308461004 cites W3195586393 @default.
• W4308461004 cites W3197576044 @default.
• W4308461004 cites W3204571096 @default.
• W4308461004 cites W3210722677 @default.
• W4308461004 cites W4200093360 @default.
• W4308461004 cites W4210511145 @default.
• W4308461004 cites W4213188921 @default.
• W4308461004 cites W4225730480 @default.
• W4308461004 doi "https://doi.org/10.1016/j.vaccine.2022.11.003" @default.
• W4308461004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36404170" @default.
• W4308461004 hasPublicationYear "2023" @default.
• W4308461004 type Work @default.
• W4308461004 citedByCount "6" @default.
• W4308461004 countsByYear W43084610042023 @default.
• W4308461004 crossrefType "journal-article" @default.
• W4308461004 hasAuthorship W4308461004A5002078534 @default.
• W4308461004 hasAuthorship W4308461004A5007224336 @default.
• W4308461004 hasAuthorship W4308461004A5014773041 @default.
• W4308461004 hasAuthorship W4308461004A5018830827 @default.
• W4308461004 hasAuthorship W4308461004A5019939863 @default.
• W4308461004 hasAuthorship W4308461004A5021310689 @default.
• W4308461004 hasAuthorship W4308461004A5021773157 @default.
• W4308461004 hasAuthorship W4308461004A5022645240 @default.
• W4308461004 hasAuthorship W4308461004A5030066738 @default.
• W4308461004 hasAuthorship W4308461004A5034272918 @default.
• W4308461004 hasAuthorship W4308461004A5045519730 @default.
• W4308461004 hasAuthorship W4308461004A5046728330 @default.
• W4308461004 hasAuthorship W4308461004A5047323010 @default.
• W4308461004 hasAuthorship W4308461004A5048412798 @default.
• W4308461004 hasAuthorship W4308461004A5049812814 @default.
• W4308461004 hasAuthorship W4308461004A5050167270 @default.
• W4308461004 hasAuthorship W4308461004A5053965140 @default.
• W4308461004 hasAuthorship W4308461004A5057514738 @default.
• W4308461004 hasAuthorship W4308461004A5058653281 @default.
• W4308461004 hasAuthorship W4308461004A5063845988 @default.
• W4308461004 hasAuthorship W4308461004A5068452972 @default.
• W4308461004 hasAuthorship W4308461004A5069182342 @default.
• W4308461004 hasAuthorship W4308461004A5071144232 @default.
• W4308461004 hasAuthorship W4308461004A5071722590 @default.
• W4308461004 hasAuthorship W4308461004A5072427629 @default.
• W4308461004 hasAuthorship W4308461004A5074231210 @default.
• W4308461004 hasAuthorship W4308461004A5078200427 @default.

• next